Market-Moving News for April 2nd
$ACOR
$AINC
$PIK
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Professional Services
Consumer Discretionary
Get the next $ACOR alert in real time by email
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 6/14/2022 | $28.00 | Outperform | Oppenheimer | |
| 12/28/2021 | $10.00 | Buy | EF Hutton |
8-K - KIDPIK CORP. (0001861522) (Filer)
8-K - KIDPIK CORP. (0001861522) (Filer)
10-Q - KIDPIK CORP. (0001861522) (Filer)
Oppenheimer initiated coverage of Ashford with a rating of Outperform and set a new price target of $28.00
EF Hutton initiated coverage of Kidpik with a rating of Buy and set a new price target of $10.00
HC Wainwright & Co. upgraded Acorda Therapeutics from Neutral to Buy and set a new price target of $10.00 from $5.00 previously
NEW YORK, NY / ACCESSWIRE / December 26, 2024 / Kidpik Corp. ("Kidpik" or the "Company"), an online clothing subscription-based e-commerce company, today announced that the Company received a notification letter from The Nasdaq Stock Market Hearings Panel (the "Panel") on December 20, 2024, indicating that trading in the Company's common stock on Nasdaq's Capital Market will be suspended effective at the open of business on December 26, 2024, based upon the Company's non-compliance with Listing Rule 5550(b)(1), the Exchange's minimum shareholders' equity rule (the "Equity Rule").The Company previously announced that on October 2, 2024, the Company received a delist determination letter from
NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Kidpik Corp. ("KIDPIK" or the "Company"), an online clothing subscription-based e-commerce company, today reported its financial results for the third quarter 2024 ended September 28, 2024.Third Quarter 2024 Highlights:Revenue, net: was $1.0 million, a year-over-year decrease of 69.2%.Gross margin: was 68.6%, compared to 61.1% in the third quarter of 2023.Shipped items: were 107,000 items, compared to 292,000 shipped items in the third quarter of 2023.Average shipment keep rate: decreased to 67.7%, compared to 82.6% in the third quarter of 2023.Net Loss: was $0.9 million or $0.45 per share, compared to $1.9 million or $1.20 per share in the thi
Kidpik Corp. ("KIDPIK" or the "Company"), an online clothing subscription-based e-commerce company, today reported its financial results for the second quarter 2024 ended June 29, 2024. Second Quarter 2024 Highlights: Revenue, net: was $1.1 million, a year-over-year decrease of 67.3%. Gross margin: was 66.2%, compared to 60.2% in the second quarter of 2023. Shipped items: were 135,000 items, compared to 290,000 shipped items in the second quarter of 2023. Average shipment keep rate: decreased to 74.6%, compared to 75.1% in the second quarter of 2023. Net Loss: was $1.3 million or $0.67 per share, compared to $2.0 million or $1.31 per share in the second quarter of 2023.
4 - Ashford Inc. (0001604738) (Issuer)
4 - Ashford Inc. (0001604738) (Issuer)
4 - Ashford Inc. (0001604738) (Issuer)
4 - Ashford Inc. (0001604738) (Issuer)
SC 13D/A - Ashford Inc. (0001604738) (Subject)
SC 13D/A - Ashford Inc. (0001604738) (Subject)
SC 13D/A - Ashford Inc. (0001604738) (Subject)
DALLAS, April 1, 2024 /PRNewswire/ -- Ashford Inc. (NYSE:AINC) ("Ashford" or the "Company") today announced that a Special Committee of independent and disinterested directors has recommended, and its Board of Directors has approved, a plan to terminate the registration of the Company's common stock under the federal securities laws following the completion of a proposed reverse stock split transaction (the "Reverse Stock Split") immediately followed by a forward stock split transaction and to delist its shares of common stock from trading on the NYSE American LLC (the "NYSE American") (the "Proposed Transaction"). It is expected that this plan would be initiated in the summer of 2024, subje
Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that it will no longer hold its fourth quarter and year end 2023 earnings conference call originally scheduled for Monday, April 1 at 4:30 p.m. ET. The Company does expect to timely file its Annual Report on Form 10-K for the period ended December 31, 2023. About Acorda Therapeutics Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. INBRIJA® is approved for intermittent treatment of OFF episodes in adults with Parkinson's disease treated with carbidopa/levodopa. INBRIJA is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor
DALLAS, March 26, 2024 /PRNewswire/ -- Ashford Inc. (NYSE:AINC) ("Ashford" or the "Company") today announced details for the release of its results for the first quarter ended March 31, 2024. Ashford plans to issue its earnings release for the first quarter after the market closes on Wednesday, May 8, 2024, and will host a conference call on Thursday, May 9, 2024, at 12:00 p.m. ET. The number to call for this interactive teleconference is (646) 960-0375. A replay of the conference call will be available through Thursday, May 16, 2024, by dialing (609) 800-9909 and entering the confirmation number, 1818099. The live broadcast of Ashford's quarterly conference call will be available online a
INSPIRE, a global event solutions company owned by Ashford Inc. (NYSE:AINC), is pleased to announce the appointment of Sayi Puligandla as Chief Operating Officer. DALLAS, Feb. 7, 2023 /PRNewswire-PRWeb/ -- INSPIRE, a global event solutions company owned by Ashford Inc. (NYSE:AINC), is pleased to announce the appointment of Sayi Puligandla as Chief Operating Officer. In this position, Puligandla will oversee human resources, hospitality operations, information technology, and other projects to support the entire organization. Puligandla brings to INSPIRE an extensive background in the hospitality industry and valuable experience in data, analytics, and building efficient operational units for
Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that Lauren Sabella, Chief Operating Officer, will resign from the Company effective September 30, 2022. Ms. Sabella will be working in a strategic advisory role for early-stage biotechnology companies. "We are grateful for Lauren's thirteen years of contributions as a member of Acorda's executive leadership team. Initially, she and her team led the commercial launch of AMPYRA, a novel treatment for multiple sclerosis. The tremendous success of that product allowed Acorda to invest in additional clinical development programs, including INBRIJA for Parkinson's disease," said Ron Cohen, M.D., Acorda's President and CEO. "Lauren has been
DALLAS, May 23, 2022 /PRNewswire/ -- Ashford Securities LLC ("Ashford Securities"), a wholly owned subsidiary of Ashford Inc. (NYSE:AINC) ("Ashford"), is pleased to announce that Ben Hilgers has been promoted to Senior Vice President, National Sales Manager. C. Jay Steigerwald III, President and Head of Distribution at Ashford Securities commented, "I have known Ben for almost twenty years and am excited to have him lead our sales efforts. Ben has a tremendous amount of experience with multiple types of products and, more importantly, has a great reputation in the industry. Ben's affable nature is complemented by his creativity and strategic thinking. We look forward to his leadership drivin